3rd CUHK Sarcoma Masterclass

Denosumab of benefit in selected patients with giant cell tumour of bone

Christina Lau, 20191014043654

Denosumab can be of benefit to patients with unresectable giant cell tumour of bone (GCTB) and those who are likely to experience significant morbidity after surgical resection of GCTB.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!

Sintilimab + bevacizumab biosimilar as 1st-line option for advanced HCC?

Pearl Toh, 08 Jan 2021

Combining the anti-PD-1 antibody sintilimab and a bevacizumab biosimilar significantly improves survival compared with the standard treatment of sorafenib in the first-line setting for patients with advanced, unresectable hepatocellular carcinoma (HCC), according to the ORIENT-32 study presented at ESMO Asia 2020.

ESMO calls for cancer patients to be prioritized for COVID-19 vaccination

Dr Margaret Shi, 4 days ago

Cancer patients at are an increased risk of severe coronavirus disease 2019 (COVID-19) and should be positioned at high priority for vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) regardless of age, according to statements issued by the European Society for Medical Oncology (ESMO).